CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum.
Maryam BehzadNegin ZirakGhazal Hamidi MadaniLinda BaidooAli RezaeiShima KarbasiMohammad SadeghiMahnaz ShafieiMahsa Mayelinull Alzheimer's Disease Neuroimaging InitiativePublished in: International journal of Alzheimer's disease (2023)
Our research suggests potential early diagnostic and prognostic utilities for certain peptides extracted from CSF-targeted proteomics research. The ethical approval of ADNI is available at ClinicalTrials.gov with Identifier: NCT00106899.